Gyre Therapeutics (NASDAQ:GYRE) and Pacira BioSciences (NASDAQ:PCRX) Critical Review

Gyre Therapeutics (NASDAQ:GYRE) and Pacira BioSciences (NASDAQ:PCRX) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, analyst recommendations, institutional ownership, dividends, profitability, earnings and risk.

Profitability

This table compares Gyre Therapeutics and Pacira BioSciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Gyre Therapeutics	-15.47%	-6.57%	-5.35%
Pacira BioSciences	1.96%	9.68%	5.30%

Volatility and Risk

Gyre Therapeutics has a beta of 1.89, indicating that its share price is 89% more volatile than the S&P 500. Comparatively, Pacira BioSciences has a beta of 0.25, indicating that its share price is 75% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Gyre Therapeutics and Pacira BioSciences, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gyre Therapeutics	2	0	1	0	1.67
Pacira BioSciences	1	4	4	0	2.33

Gyre Therapeutics currently has a consensus target price of $16.00, suggesting a potential upside of 125.04%. Pacira BioSciences has a consensus target price of $30.14, suggesting a potential upside of 19.57%. Given Gyre Therapeutics’ higher possible upside, equities analysts clearly believe Gyre Therapeutics is more favorable than Pacira BioSciences.

Valuation & Earnings

This table compares Gyre Therapeutics and Pacira BioSciences”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gyre Therapeutics	$116.59 million	6.80	$5.03 million	($0.21)	-33.86
Pacira BioSciences	$726.41 million	1.38	$7.03 million	$0.35	72.03

Pacira BioSciences has higher revenue and earnings than Gyre Therapeutics. Gyre Therapeutics is trading at a lower price-to-earnings ratio than Pacira BioSciences, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

24.0% of Gyre Therapeutics shares are held by institutional investors. Comparatively, 99.7% of Pacira BioSciences shares are held by institutional investors. 9.5% of Gyre Therapeutics shares are held by company insiders. Comparatively, 6.4% of Pacira BioSciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Pacira BioSciences beats Gyre Therapeutics on 10 of the 14 factors compared between the two stocks.

About Gyre Therapeutics

Gyre Therapeutics, Inc., a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases. In addition, it advances a product pipeline in China, including Pirfenidone, for dermatomyositis interstitial lung disease, systemic sclerosis-associated interstitial lung disease, and pneumoconiosis, as well as for diabetic kidney disease; and product candidates for acute-on-chronic liver failure, chronic obstructive pulmonary disease, and pulmonary arterial hypertension. The company was founded in 2002 and is headquartered in San Diego, California.

About Pacira BioSciences

Pacira Biosciences, Inc. is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.